On Location

On Location

Updates from major medical meetings in the field of hematology/oncology

Investigational CAR T-Cell Therapy Improves Objective Response Rate in Patients With Aggressive NHL

At the 2017 AACR Annual Meeting, Frederick L. Locke, MD, from the H. Lee Moffitt Cancer Center & Research Institute in Tampa, Florida, and...

Investigational Drug TEW-7197 Improves Myeloma Outcomes Both as Single Agent and in Combination With...

TGF-β, a multifunctional cytokine, is produced in multiple myeloma (MM) cells and cells in the bone marrow (BM) tumor microenvironment (TME), where it also...

BION-1301 May Improve Survival and Inhibit Treatment Resistance for Patients With Myeloma

In a preclinical study presented at the 2017 AACR Annual Meeting, BION-1301, an anti-human APRIL blocking antibody, inhibited the survival of multiple myeloma (MM)...

CHRONOS-1: Copanlisib Shows Promise for Patients With Relapsed/Refractory Indolent B-Cell NHL

Patients with relapsed/refractory indolent B-cell lymphomas often have limited options beyond standard therapies once their disease progresses. Copanlisib, an intravenously administered pan-class I phosphatidylinositol...

A Tale of Two Proteasome Inhibitors: Carfilzomib Versus Bortezomib in Multiple Myeloma

At the 16th International Myeloma Workshop (IMW), two clinical trials of patients with newly diagnosed and relapsed/refractory multiple myeloma (NDMM; RRMM) showed disparate results....

Denosumab Delays Skeletal-Related Events in Newly Diagnosed Multiple Myeloma

Denosumab (a monoclonal antibody that targets the RANK ligand) was noninferior to zoledronic acid (ZA) in delaying the time to a first skeletal-related event...

The Multiple Myeloma Genome Project: Developing a Risk Stratification System for Multiple Myeloma

An update from the Multiple Myeloma Genome Project (MMGP), presented at the 16th International Myeloma Workshop (IMW), revealed several associations between the development of...

Early Studies Reveal Efficacy, Safety Concerns With Vadastuximab Talirine in Patients With Acute Myeloid...

Early studies of vadastuximab talirine (33A) in patients with acute myeloid leukemia (AML) have shown preliminary efficacy, whether the drug has been used as...

Phase I Study Shows Venetoclax Active in Patients With Relapsed/Refractory Myeloma

The B-cell lymphoma/leukemia-2 (BCL-2) inhibitor venetoclax may be a new option for patients with heavily treated multiple myeloma (MM), according to results from an...

Newly Approved Drugs: How to Use Them in Practice

In 2016, the U.S. Food and Drug Administration (FDA) approved several new therapies for the treatment of hematologic disorders, marking several “firsts” for hematology,...
Advertisement

Current Issue

May 2017, Volume 3, Issue 6

This issue discusses the legacy of Agent Orange and hematologic malignancies, a debate over transplant in myelodysplastic syndromes, and more.